Dr. Elgavish's research has centered on the development of Magnetic Resonance Imaging (MRI) methods for the early diagnosis and quantification of disease, including Ischemic Heart Disease (IHD), Mesial Temporal Lobe Epilepsy (MTLE), and Prostate Cancer (PC). The central theme in these methods has been the development of paramagnetic contrast agents that enhance MRI and enable it to provide images that highlight diseased areas with high spatial resolution. These agents are then applied to studies in experimental animal models in the case of IHD and PC. Additional activity in the lab consists of the development and application of software to quantify the extent of disease based on the MRI images obtained from the animal studies in IHD and PC, and from results of human studies in MTLE. Dr. Elgavish's research has been funded throughout the years mainly by the NIH and by industry.
Gabriel A. Elgavish (b. 1942) received his B.S. degree in Chemistry from the Hebrew University of Jerusalem (1967), and his M.S. degree from Tel-Aviv University (1972). He did graduate studies in NMR spectroscopy at the Weizmann Institute of Science in Rehovot, Israel (Ph.D. 1978). His interest in biological systems continued during two years of postdoctoral studies at the NIH. A Professor of Biochemistry and Molecular Genetics, Dr. Elgavish joined the UAB faculty in 1981. His research is currently funded by NIH and the pharmaceutical industry.